In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors). The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016.
The U.S. region constituted approximately 36% of the total market for drugs used to treat liver disease in 2010 and was valued at $4.5 billion. In 2011, the market continued to decrease and will hit nearly $4.2 billion. BCC expects this market to increase in the future rising at a CAGR of 3% to reach nearly $4.9 billion by 2016.
The European market constituted approximately 31% of the total market and was $3.8 billion in 2010. This market is expected to see a decrease in 2011 totaling nearly $3.6 billion. This market is forecast to grow at a CAGR of 1% and should be worth $3.7 billion by 2016.